GlassScriptPhysician profile
Richard Baker Saint
NPI 1851313373
$5,263.75
in general payments reported to CMS, 2019-2025
34 companies · $677 in 2025
The $677 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $289 · 2021: $295 · 2022: $180 · 2023: $2,332 · 2024: $1,335 · 2025: $677.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,711 · Travel and Lodging: $1,517 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,710.99 |
| Travel and Lodging | $1,517.48 |
| Education | $115.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,495.99 | 2020-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Spaceoar System |
| Sumitomo Pharma America, INC. | $333.22 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $305.77 | 2019-2025 | Xtandi, Myrbetriq |
| Teleflex LLC | $300.31 | 2021-2023 | Urolift |
| Pfizer INC. | $262.86 | 2019-2025 | |
| Abbvie INC. | $252.14 | 2019-2024 | Botox, Lupron Depot |
| Accord Healthcare, INC. | $189.30 | 2023-2025 | |
| Urogen Pharma, INC. | $128.93 | 2023-2024 | Jelmyto |
| Bioprotect Medical, INC. | $112.26 | 2025 | Bioprotect Balloon Implant System |
| Axonics, INC. | $94.14 | 2021-2023 | Bulkamid, Axonics |
| Antares Pharma, INC. | $76.61 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Medtronic, INC. | $69.88 | 2024-2025 | Interstim |
| Myovant Sciences INC. | $63.95 | 2021 | |
| Procept Biorobotics Corporation | $62.74 | 2024 | Aquabeam System |
| Endo Pharmaceuticals INC. | $53.51 | 2019-2023 | Xiaflex |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $42.64 | 2020 | |
| Polynovo North America LLC | $35.17 | 2024 | Novosorb Btm |
| Caldera Medical, INC | $34.61 | 2021-2022 | |
| Allergan, INC. | $31.21 | 2019-2020 | |
| Endo USA, INC. | $29.74 | 2025 | Xiaflex |
| Biocomposites INC | $27.44 | 2025 | Stimulan |
| Vertex Pharmaceuticals Incorporated | $25.92 | 2025 | |
| Progenics Pharmaceuticals, INC. | $24.20 | 2023 | Pylarify |
| Travere Therapeutics, INC. | $24.09 | 2020 | |
| Ambu INC. | $23.76 | 2025 | |
| Ferring Pharmaceuticals INC. | $23.17 | 2024 | Adstiladrin |
| 180 Medical, INC. | $21.10 | 2025 | |
| Coloplast Corp | $19.40 | 2023 | Speedicath |
| Calyxo, INC. | $17.99 | 2025 | Cvac Aspiration System |
| Halozyme INC | $17.77 | 2023 | |
| Verity Pharmaceuticals INC. | $17.07 | 2024 | Trelstar |
| Kowa Pharmaceuticals America, INC. | $16.12 | 2023 | Seglentis |
| Tolmar, INC. | $16.09 | 2023 | |
| Azurity Pharmaceuticals, INC. | $14.65 | 2025 | Azmiro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Saint listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.